An interventional study of CyberKnife Radiosurgery in Tumor, Benign, Optic Nerve, sponsored by Community Cancer Center, Normal, Illinois. Completed at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2019-07-25.
Sponsored by Community Cancer Center, Normal, Illinois · Not applicable, Interventional, and Treatment
The purpose of this study is to find out what effects (good and bad) CyberKnife stereotactic radiosurgery has on tumors near the critical structures of the eye (optic apparatus).
The investigators hypothesize that hypofractionated stereotactic radiotherapy via the CyberKnife ® can deliver tumor ablating doses of radiation to perioptic lesions safely and effectively while sparing the adjacent optic apparatus and normal brain tissues from receiving damaging doses of radiation.
The CyberKnife system is a type of radiation machine that uses a special system to precisely focus large doses of x-rays (radiation) on the tumor. The device is designed to concentrate large doses of radiation onto the tumor so that injury from radiation to the nearby normal tissue will be minimal.
Community Cancer Center, Normal, Illinois is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Radiation: CyberKnife Radiosurgery
25 Gy delivered in 5 fractions of 5 Gy per fraction
Also known as: CyberKnife
Tumor status
To determine the local control rate of patients with perioptic lesions treated with stereotactic CyberKnife radiosurgery.
Time frame: 5 years
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Optic Nerve Neoplasms
Community Cancer Center, Normal, Illinois